Skip to main content
SpringerLink
Log in

The incidence of neoplasia in patients receiving tumour necrosis factor (TNF) antagonists appears to be less than 4%, with solid tumours being most frequent

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. De Abreu Trigueros P, Granados Bautista P, Laíño Piñeiro M, Varas de Dios B, Burguet i Arfelis A, Castro Pérez P, Zea Mendoza A.Neoplasia incidence on patients diagnosed with rheumatoid arthritis under anti-TNF treatment. 2007 Annual European Congress of Rheumatology: abstr. AB0295, 13 Jun 2007

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

The incidence of neoplasia in patients receiving tumour necrosis factor (TNF) antagonists appears to be less than 4%, with solid tumours being most frequent. React. Wkly. 1160, 4 (2007). https://doi.org/10.2165/00128415-200711600-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200711600-00010

Keywords

Search

Navigation